According to seven experts, who recently provided their 2023 price targets for Madrigal Pharmaceuticals, the average price target is $175.00, with a high estimate of $203.00 and a low estimate of $131.00. That is a potential downside of approximately -32.68% from the last closing price of $259.94 on June, 2023.

$175.00

-32.68% Downside

Outperform

Madrigal Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Price for Madrigal Pharmaceuticals has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $247.52 – an increase of 100.00%. Over the next nine years, experts anticipate that Fair Value growth for Madrigal Pharmaceuticals will be 100.00%.

2022 Fair Value Forecast

$247.52

2023 Fair Value Forecast

$276.60

2024 Fair Value Forecast

$307.55

2025 Fair Value Forecast

$341.97

2026 Fair Value Forecast

$380.24

2027 Fair Value Forecast

$422.79

2028 Fair Value Forecast

$470.10

2029 Fair Value Forecast

$522.70

2030 Fair Value Forecast

$581.19

Madrigal Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

Madrigal Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Madrigal Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Madrigal Pharmaceuticals's Free Cash Flow has grown, increasing from $-41.79M to $-184.25M – an increase of 340.89%. For the following year, the 0 analysts predict that Madrigal Pharmaceuticals's Free Cash Flow will drop by 34.05%, reaching $-121.51M. In 2030, the professionals' prediction is that MDGL's Free Cash Flow will decrease by 26.48%, reaching $-135.47M.

2022 FCF Forecast

$-121512875.00

2023 FCF Forecast

$-106846270.99

2024 FCF Forecast

$-125027944.77

2025 FCF Forecast

$-146207678.61

2026 FCF Forecast

$-138751087.00

2027 FCF Forecast

$-127808251.27

2028 FCF Forecast

$-127569675.87

2029 FCF Forecast

$-133573955.28

2030 FCF Forecast

$-135466252.98

Madrigal Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Madrigal Pharmaceuticals's Net Income has increased by 188.09%, going from $-83.95M to $-241.85M. 0 analysts predict Madrigal Pharmaceuticals's Net Income will decrease by 30.42% in the next year, reaching $-168.29M. By 2030, professionals predict that Madrigal Pharmaceuticals's Net Income will decrease by 24.31%, to $-183.06M.

2022 NI Forecast

$-168287291.67

2023 NI Forecast

$-150807851.64

2024 NI Forecast

$-170372656.92

2025 NI Forecast

$-195258423.01

2026 NI Forecast

$-187031534.79

2027 NI Forecast

$-174668750.34

2028 NI Forecast

$-173929319.30

2029 NI Forecast

$-180834313.27

2030 NI Forecast

$-183058575.33

Madrigal Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

Madrigal Pharmaceuticals's EBITDA has increased by 155.20% In the last two years, going from $-94.86M to $-242.08M. In the following year, the 0 analysts surveyed believe that Madrigal Pharmaceuticals's EBITDA will decrease by 27.88%, reaching $-174.59M. According to professionals, by 2030, Madrigal Pharmaceuticals's EBITDA will have decreased by 22.64%, falling down to $-187.27M.

2022 EBITDA Forecast

$-174588096.00

2023 EBITDA Forecast

$-157036172.75

2024 EBITDA Forecast

$-175367528.65

2025 EBITDA Forecast

$-198393285.16

2026 EBITDA Forecast

$-191198222.02

2027 EBITDA Forecast

$-179535130.47

2028 EBITDA Forecast

$-178727222.39

2029 EBITDA Forecast

$-185107784.23

2030 EBITDA Forecast

$-187267375.04

Madrigal Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Madrigal Pharmaceuticals's EBIT has grown, increasing from $-94.97M to $-242.48M – a growth of 155.32%. The next year, 0 experts forecast that Madrigal Pharmaceuticals's EBIT will decrease by 27.86%, reaching $-174.92M. In 2030, professionals predict that Madrigal Pharmaceuticals's EBIT will decrease by 22.63%, reaching $-187.61M.

2022 EBIT Forecast

$-174916989.33

2023 EBIT Forecast

$-157314509.64

2024 EBIT Forecast

$-175694088.18

2025 EBIT Forecast

$-198745152.55

2026 EBIT Forecast

$-191543953.19

2027 EBIT Forecast

$-179859772.05

2028 EBIT Forecast

$-179056398.40

2029 EBIT Forecast

$-185448711.82

2030 EBIT Forecast

$-187612280.13

Madrigal Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, EPS for Madrigal Pharmaceuticals has grown by 168.44%, going from $-5.45 to $-14.63. According to 0 analysts, Madrigal Pharmaceuticals's EPS will fall by 26.48% in the next year, reaching $-10.76. Professionals believe that By 2030, Madrigal Pharmaceuticals's EPS will fall to $-11.47 – a 21.61% decrease from its current value.

2022 EPS Forecast

$-10.76

2023 EPS Forecast

$-9.58

2024 EPS Forecast

$-10.78

2025 EPS Forecast

$-12.12

2026 EPS Forecast

$-11.72

2027 EPS Forecast

$-10.98